Search - tctmd.com

Displaying 221 - 240 of 312

Sort: Relevancy | Date

Presentation NY Valves 2024

M3

Presenter: David Daniels

June 06, 2024

Presentation NY Valves 2024

Intrepid

Presenter: Martin B. Leon

June 06, 2024

Presentation NY Valves 2024

T-TEER in a Broad Range of Anatomies: Results From the TRILUMINATE Pivotal Trial

Presenter: Brian K. Whisenant

June 06, 2024

Presentation NY Valves 2024

The Future of Transcatheter Tricuspid Intervention: What’s Missing in Technology and Clinical Trials?

Presenter: Azeem Latib

June 06, 2024

Presentation NY Valves 2024

Will New VHD Screening Methods Address or Exacerbate Healthcare Disparities?

Presenter: Suzanne J. Baron

June 06, 2024

Presentation NY Valves 2024

Asymmetric Expansion of Balloon Expandable Transcatheter Aortic Valve Prostheses: Implications for Valve Hemodynamics and Clinical Outcomes

Presenter: Annette Maznyczka

June 06, 2024

Presentation NY Valves 2024

Designing Trials to Assess the Effectiveness of New VHD Screening Strategies

Presenter: Timothy Joseph Poterucha

June 06, 2024

Presentation NY Valves 2024

Metanalysis of Clinical and Hemodynamic Differences in Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus

Presenter: Errol Christopher Moras

June 06, 2024

Presentation NY Valves 2024

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

Presenter: Mark Lebehn

June 06, 2024

Presentation NY Valves 2024

Screening for VHD: Beyond Proof of Concept to Implementation and Scaling

Presenter: Sammy Elmariah

June 06, 2024

Presentation NY Valves 2024

The Landscape of Novel Methods to Screen for VHD

Presenter: Sreekanth Vemulapalli

June 06, 2024

Presentation NY Valves 2024

Long-Term Clinical Outcomes of “SMART-Like” Patients With Small Aortic Annuli

Presenter: Hanad I. Bashir

June 06, 2024

Presentation NY Valves 2024

The Importance of Patient Reported Outcomes in VHD

Presenter: Suzanne V. Arnold

June 06, 2024

Presentation NY Valves 2024

Clinical Characteristics and Outcomes of High Gradient Aortic Stenosis Undergoing TAVR

Presenter: Shivabalan Kathavarayan Ramu

June 06, 2024

Presentation NY Valves 2024

The Clinical Impact of Moderate AS

Presenter: Nicolas M. Van Mieghem

June 06, 2024

Presentation NY Valves 2024

Diversity and Under Represented Populations in VHD: Focusing on Real Solutions

Presenter: Annetine C. Gelijns, Megan Coylewright

June 06, 2024

Presentation NY Valves 2024

Asymptomatic Severe AS – A Clinician’s Perspective

Presenter: Robert O. Bonow

June 06, 2024

Presentation NY Valves 2024

Using Real-world Data in VHD: Sources, Successes, and Failures

Presenter: Sreekanth Vemulapalli

June 06, 2024

Presentation NY Valves 2024

Long-term Follow-up in VHD Clinical Trials: Much Needed, BUT Difficult to Do

Presenter: Mauro Moscucci

June 06, 2024

Presentation NY Valves 2024

Interpretation of PROs: Understanding Validity and Clinically-Important Differences

Presenter: Suzanne V. Arnold

June 06, 2024

Advertisement

M3

Intrepid

T-TEER in a Broad Range of Anatomies: Results From the TRILUMINATE Pivotal Trial

The Future of Transcatheter Tricuspid Intervention: What’s Missing in Technology and Clinical Trials?

Will New VHD Screening Methods Address or Exacerbate Healthcare Disparities?

Asymmetric Expansion of Balloon Expandable Transcatheter Aortic Valve Prostheses: Implications for Valve Hemodynamics and Clinical Outcomes

Designing Trials to Assess the Effectiveness of New VHD Screening Strategies

Metanalysis of Clinical and Hemodynamic Differences in Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

Screening for VHD: Beyond Proof of Concept to Implementation and Scaling

The Landscape of Novel Methods to Screen for VHD

Long-Term Clinical Outcomes of “SMART-Like” Patients With Small Aortic Annuli

The Importance of Patient Reported Outcomes in VHD

Clinical Characteristics and Outcomes of High Gradient Aortic Stenosis Undergoing TAVR

The Clinical Impact of Moderate AS

Diversity and Under Represented Populations in VHD: Focusing on Real Solutions

Asymptomatic Severe AS – A Clinician’s Perspective

Using Real-world Data in VHD: Sources, Successes, and Failures

Long-term Follow-up in VHD Clinical Trials: Much Needed, BUT Difficult to Do

Interpretation of PROs: Understanding Validity and Clinically-Important Differences

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content